Oct 23, 2025 06:03AM
Oct 23, 2025 06:01AM
Sep 30, 2025 07:01AM
Sep 30, 2025 07:00AM
Sep 10, 2025 06:01AM
Sep 10, 2025 06:00AM
Jul 17, 2025 07:00AM NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type
Jul 17, 2025 07:00AM
Jun 16, 2025 07:00AM
Apr 15, 2025 09:02AM
Apr 15, 2025 09:00AM
Mar 10, 2025 07:04AM
Mar 10, 2025 07:00AM
Feb 25, 2025 09:05AM Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Jan 28, 2025 07:32AM
Jan 28, 2025 07:30AM
Dec 19, 2024 07:31AM
Dec 19, 2024 07:30AM
Nov 4, 2024 07:03AM
Nov 4, 2024 07:00AM
Jul 29, 2024 07:02AM NLS Pharmaceutics (NLSP) and Kadimastem Announce Binding Term Sheet to Merge
Jul 29, 2024 07:00AM
Dec 29, 2023 04:32PM
Dec 29, 2023 04:30PM
Dec 1, 2023 07:30AM
Aug 28, 2023 07:31AM
Aug 28, 2023 07:30AM
Jul 3, 2023 07:02AM NLS Pharmaceutics (NLSP) to Proceed with Phase 3 Clinical Program for Mazindol ER
Jul 3, 2023 07:00AM
Jun 14, 2023 07:32AM
Jun 14, 2023 07:30AM
May 8, 2023 08:32AM
May 8, 2023 08:30AM
May 2, 2023 08:54AM
May 2, 2023 08:45AM NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
Mar 27, 2023 08:30AM
Jan 30, 2023 08:30AM
Jan 23, 2023 08:33AM
Jan 23, 2023 08:30AM
Jan 10, 2023 08:30AM
Dec 22, 2022 08:33AM
Dec 22, 2022 08:30AM NLS Pharmaceutics CEO Issues Letter to Shareholders
Dec 20, 2022 09:07AM
Dec 20, 2022 09:05AM
Dec 14, 2022 08:30AM
Dec 7, 2022 08:29AM
Dec 7, 2022 08:28AM
Dec 7, 2022 08:25AM
Dec 7, 2022 08:25AM NLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P. to Raise Aggregate Gross Proceeds of up to $30 Million
Nov 23, 2022 08:32AM

322,233 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All